CJC-1295 + Ipamorelin · pharmacokinetics · research use only
CJC-1295 / Ipamorelin half-life: a blend on two short clocks.
The single most common half-life mistake on this blend is assuming it lasts a week. That figure belongs to CJC-1295 with DAC — a different molecule. Titan's blend is the no-DAC version (Modified GRF 1-29) paired with Ipamorelin, and both components clear fast: CJC-1295 no-DAC on the order of ~30 minutes, Ipamorelin around ~2 hours. This page explains why the DAC/no-DAC distinction changes the kinetics completely, how the two short clocks shape research cadence, and why it is a laboratory reference — not a human protocol or medical advice.
DAC vs no-DAC is the whole question
CJC-1295 exists in two forms. With DAC (a Drug Affinity Complex that binds serum albumin) the half-life stretches to roughly 6-8 days. Without DAC — Modified GRF 1-29, the form in Titan's blend — there is no albumin anchor, so it clears in about 30 minutes. Quoting the 6-8 day number for a no-DAC blend is the most frequent error in the literature summaries, and it changes everything downstream.
CJC-1295 vs Ipamorelin →CJC-1295 no-DAC: ~30 minutes
As Modified GRF 1-29, the GHRH-analog component is reported with a plasma half-life on the order of 30 minutes (sources cite roughly 30-60). It is studied to deliver a sharp, short GHRH-like pulse rather than a sustained elevation — which is precisely the behaviour the no-DAC form is selected for in pulsatile-release research models.
How that shapes cadence →Ipamorelin: ~2 hours
The GHRP component, Ipamorelin, is reported with a half-life of approximately 2 hours, with its action tapering after that window. It is studied as a selective ghrelin-receptor agonist — the second of the two receptors this blend is built to engage — running on a slightly longer clock than the no-DAC GHRH analog beside it.
Ipamorelin vs MK-677 →Two receptors, two short windows
The blend's logic is that a GHRH analog and a GHRP act on different receptors and are studied together. Because both clear within hours rather than days, research protocols model frequent, smaller administrations timed to the pulse — not a once-weekly schedule. The cadence follows the two short half-lives, not the DAC version's week-long curve.
The pairing rationale →A blend COA must prove both
Two peptides in one vial means one purity number is not enough. A lot-matched certificate should confirm the identity of both the GHRH analog and the GHRP by mass spec, the ratio between them, and purity for each — because a kinetic model built on the wrong ratio is wrong. Titan ships the 5mg/5mg blend with an HPLC main-peak result against a ≥99% internal purity target and mass-spec identity confirmation on a lot-matched release sheet.
How to read a blend COA →Research-use framing
Neither CJC-1295 nor Ipamorelin has regulatory approval for human use. The half-life figures here are reproduced as a laboratory reference for in-vitro and modelling work, not instructions for human use. Titan supplies the blend strictly as a research reagent, and nothing on this page is medical or dosing advice.
Research-use policy →The detail, in plain terms
The two clocks, side by side.
This blend only makes sense once the no-DAC half-lives are read correctly — and once the DAC version is set aside as a different molecule. These are the figures a research protocol weighs, reproduced as a reference, not a human protocol.
- Blend
- CJC-1295 (no-DAC / Modified GRF 1-29) + Ipamorelin — 5mg/5mg, $119.99.
- CJC-1295 no-DAC half-life
- Short — reported on the order of ~30 minutes (30-60).
- CJC-1295 with DAC (for contrast)
- ~6-8 days — a different molecule, NOT what this blend contains.
- Ipamorelin half-life
- Approximately ~2 hours.
- Resulting cadence
- Frequent, smaller administrations timed to the pulse — not weekly.
- Format
- 5mg/5mg lyophilized blend — reconstitute before in-vitro use.
Questions researchers ask
Before you order.
- What is the half-life of the CJC-1295 / Ipamorelin blend?
- It runs on two short clocks. Titan's blend uses no-DAC CJC-1295 (Modified GRF 1-29), reported with a plasma half-life on the order of ~30 minutes, paired with Ipamorelin at approximately ~2 hours. Neither component lasts days. The frequently-quoted 6-8 day figure belongs to CJC-1295 with DAC, which is a different molecule and is not what this blend contains.
- Why do people say CJC-1295 lasts a week?
- Because they are quoting the DAC version. CJC-1295 with DAC carries a Drug Affinity Complex that binds serum albumin and extends its half-life to roughly 6-8 days. The no-DAC form — Modified GRF 1-29, the form in Titan's blend — has no albumin anchor and clears in about 30 minutes. The DAC/no-DAC distinction is the single most important thing to get right before modelling this compound.
- How does the half-life shape research cadence for this blend?
- Because both components clear within hours, research protocols model frequent, smaller administrations timed to a pulse rather than a once-weekly schedule. The cadence follows the two short half-lives. See the blend dosage reference for the reconstitution math and the modelled windows — framed as a laboratory reference, not a human protocol.
- Does the blend ratio affect the kinetics on the COA?
- Yes. Two peptides in one vial means the certificate should confirm the identity of both the GHRH analog and the GHRP by mass spec, the ratio between them, and purity for each. A kinetic model built on the wrong ratio is wrong. Titan's 5mg/5mg blend ships with an HPLC main-peak result against a ≥99% internal purity target and mass-spec identity confirmation on a lot-matched release sheet.
- Is CJC-1295 or Ipamorelin approved for human use?
- No. Neither compound has regulatory approval for human use. Titan Peptide Lab supplies the blend strictly as a research-use-only reagent for in-vitro laboratory work — not for human or animal consumption, and not for diagnostic, therapeutic, or preventative use.